Found 4335 clinical trials
A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX (cetuximab) in adults with recurrent and/or metastatic solid tumors.
- 0 views
- 19 Feb, 2024
- 6 locations
Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments
Human papilloma virus (HPV) is responsible of the most common sexually transmitted infection. It can cause severe cancer lesions, of the cervix, vulva, vagina, penis and oropharynx. The International Agency for Cancer Research of World Health Organization (WHO) classified a dozen of HPV related high-risk cancer types, and recognized cervical …
- 0 views
- 19 Feb, 2024
- 1 location
Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-na ve GBM Patients.
A multi-center, open-label, single-arm, phase I/II clinical study is designed to test the safety and immunogenicity of an investigational Dendritic and Glioma Cells Fusion vaccine given with IL-12 for treatment-nave patients after resection of glioblastoma.
- 0 views
- 19 Feb, 2024
- 2 locations
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors
Hepatic metastases are common in solid cancers (up to 30% of patients with colorectal cancer and up to 50% of patients during their follow-up). The incidence of primary liver cancer increases due to the increase in chronic liver diseases induced by excessive alcohol consumption, hepatitis B and C viruses, and …
- 0 views
- 19 Feb, 2024
- 1 location
A Study of SGN-B6A in Advanced Solid Tumors
This trial will look at a drug called SGN-B6A to find out whether it is safe for people who have solid tumors. It will study SGN-B6A to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether …
- 0 views
- 19 Feb, 2024
- 3 locations
Altered Tumor Oxygenation by Metformin a Potential Step in Overcoming Radiotherapy Resistance in LACC
Poor tumor oxygenation (hypoxia) is an established negative prognostic and predictive factor in locally advanced cervical cancer (LACC). Hypoxia-modifying measures implemented in the clinic are lacking.
- 0 views
- 19 Feb, 2024
- 1 location
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers.
- 0 views
- 19 Feb, 2024
- 39 locations
Lenvatinib and Pembrolizumab Before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer
Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
- 8 views
- 19 Feb, 2024
- 1 location
RISI in the Treatment of Recurrent Metastatic SCC of Thoracic Inlet Lymph Nodes
The malignant tumor at the thoracic entrance is difficult to be surgically removed, and radiotherapy or radiotherapy based comprehensive treatment is often chosen at the initial diagnosis.
- 0 views
- 19 Feb, 2024
- 1 location
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
- 0 views
- 19 Feb, 2024
- 1 location